NEW YORK (360Dx) – A new collaboration was announced today aimed at shedding light on differences in type 2 diabetes.
Roche Diagnostics, Eli Lilly, the Indiana Biosciences Research Institute, the Regenstrief Institute, and Indiana University School of Medicine are collaborating to better understand how T2D varies among patients, with the goal of developing improved diagnostic tools and new treatments.
Data from Regenstrief's Indiana Network of Patient Care database will be analyzed as part of the project, which is anticipated to be completed in the second quarter of 2017. The partners will have access to information from more than 800,000 T2D patients, IBRI said.
Brian Heald, head of global R&D for Roche Diabetes Care, said that the project will help the firm understand "the future potential to utilize predictive computational phenotyping to establish solutions for patients that help avoid disease complications and disease progression."